BCNU Wafer + Irinotecan + Bevacizumab
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Jun 1, 2009 → Jun 1, 2010
NCT ID
NCT00984438About BCNU Wafer + Irinotecan + Bevacizumab
BCNU Wafer + Irinotecan + Bevacizumab is a phase 1/2 stage product being developed by Eisai for Glioblastoma Multiforme. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00984438. Target conditions include Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00984438 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Glioblastoma Multiforme